Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(27)
•••
Comment by Ticklel1ston Apr 12, 2019 11:15am
172 Views
Post# 29618611

RE:RE:RE:RE:What about Back to Back NRS?

RE:RE:RE:RE:What about Back to Back NRS?Jewals99...you get it.

I doubt a buyout is in the cards as the MOU is taking an equity position which most likley is attached to a couple of board seats and a significant say in how the sirona is run.

And I can't help but think WANGBANG is ridding the bus as well. Makes business sense to me to have PRC deal with them.

The ROFR deal might be on shakey ground as they had 30 days to firm up and that is probaly past. So the NR on the results is letting everyone know Sirona is open for business on 1067 worldwide rights. Might be time to bring PRC into this one as well. Maybe they are?? Just speculation.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities